Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Results Achieved with Handheld Diagnostic Platform

By LabMedica International staff writers
Posted on 19 Mar 2013
A functional prototype of a new handheld system for on-the-spot diagnostic results has been completed.

The AgPlus Diagnostics (Bedfordshire, United Kingdom) platform utilizes electrochemical immunoassay technology in a microfluidic chip format. More...
The signalling and measurement system, based on the detection of amplified silver ions by anodic stripping voltammetry, allows sensitive, accurate, and quantifiable results to be obtained from a small sample volume (50 µL) within minutes. No sample preparation is required, making it ideal for multiple sample types and for testing in a range of settings.

The AgPlus technology prototype demonstrates an assay for human Troponin I, a cardiac marker used in clinical settings. The AgPlus Troponin I assay is currently showing a dynamic range of 0.1–50 ng/mL in a nonoptimized format with assay run times of 10 minutes. AgPlus tests for cortisol and testosterone are being developed, which will be applicable in sports science applications.

Via a portable handheld device (with WiFi and Bluetooth technology for storage and communication of results), AgPlus technology offers fully quantitative laboratory-equivalent analysis of multiple analytes from a single sample.

“The first working AgPlus technology system prototype is an important milestone for AgPlus Diagnostics, demonstrating the successful coming together of this novel diagnostic assay and its unique analytical platform to achieve a fully functional, portable system that can deliver accuracy and sensitivity that’s on a par with laboratory analyzers,” commented Keith Page, CEO of Agplus Diagnostics.

Related Links:
AgPlus Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.